Which has better earnings and valuation, OGI or TLRY?

Organigram has higher earnings, but lower revenue than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organigram C$309.18M 0.74 -C$57.23M C$0.60 2.65 Tilray Brands C$915.45M 0.94 -C$183.24M -C$1.09 N/A

Do analysts prefer OGI or CMED?

Organigram presently has a consensus target price of C$3.13, indicating a potential upside of 96.54%. Given Organigram's stronger consensus rating and higher possible upside, analysts plainly believe Organigram is more favorable than CanniMed Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organigram 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 CanniMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, OGI or CMED?

CanniMed Therapeutics has lower revenue, but higher earnings than Organigram. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organigram C$309.18M 0.74 -C$57.23M C$0.60 2.65 CanniMed Therapeutics N/A N/A N/A N/A N/A

Which has stronger earnings and valuation, OGI or WEED?

Organigram has higher revenue and earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organigram C$309.18M 0.74 -C$57.23M C$0.60 2.65 Canopy Growth C$293.63M 2.07 -C$1.05B -C$0.67 N/A

Do analysts recommend FRX or OGI?

Organigram has a consensus target price of C$3.13, suggesting a potential upside of 96.54%. Given Organigram's higher possible upside, analysts clearly believe Organigram is more favorable than Fennec Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Organigram 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts prefer VGW or OGI?

Organigram has a consensus target price of C$3.13, indicating a potential upside of 96.54%. Given Organigram's stronger consensus rating and higher probable upside, analysts clearly believe Organigram is more favorable than Valens GroWorks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valens GroWorks 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Organigram 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger earnings & valuation, VGW or OGI?

Valens GroWorks has higher earnings, but lower revenue than Organigram. Valens GroWorks is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Valens GroWorks C$27.50M 13.96 -C$22.41M -C$0.18 N/A Organigram C$309.18M 0.74 -C$57.23M C$0.60 2.65

Organigram (OGI) Competitors

C$1.59 +0.01 (+0.63%)

As of 09/4/2026 03:59 PM Eastern

Compare

OGI vs. TLRY, CMED, WEED, FRX, and VGW

Should you buy Organigram stock or one of its competitors? Organigram's main competitors and comparable companies include Tilray Brands (TLRY), CanniMed Therapeutics (CMED), Canopy Growth (WEED), Fennec Pharmaceuticals (FRX), and Valens GroWorks (VGW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Organigram compare to Tilray Brands?

Organigram (TSE:OGI) and Tilray Brands (TSE:TLRY) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

Organigram has higher earnings, but lower revenue than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram	C$309.18M	0.74	-C$57.23M	C$0.60	2.65
Tilray Brands	C$915.45M	0.94	-C$183.24M	-C$1.09	N/A

In the previous week, Organigram's average media sentiment score of 0.00 equaled Tilray Brands'average media sentiment score.

Company	Overall Sentiment
Organigram	Neutral
Tilray Brands	Neutral

Organigram has a net margin of 28.02% compared to Tilray Brands' net margin of -15.22%. Organigram's return on equity of 21.99% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram	28.02%	21.99%	-5.56%
Tilray Brands	-15.22%	-8.85%	-1.41%

Organigram presently has a consensus target price of C$3.13, indicating a potential upside of 96.54%. Tilray Brands has a consensus target price of C$13.30, indicating a potential upside of 113.48%. Given Tilray Brands' higher possible upside, analysts clearly believe Tilray Brands is more favorable than Organigram.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tilray Brands	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

3.6% of Organigram shares are held by institutional investors. Comparatively, 4.2% of Tilray Brands shares are held by institutional investors. 31.3% of Organigram shares are held by company insiders. Comparatively, 0.7% of Tilray Brands shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Organigram has a beta of 1.779518, indicating that its stock price is 78% more volatile than the broader market. Comparatively, Tilray Brands has a beta of 3.215277, indicating that its stock price is 222% more volatile than the broader market.

Summary

Organigram beats Tilray Brands on 8 of the 14 factors compared between the two stocks.

How does Organigram compare to CanniMed Therapeutics?

Organigram (TSE:OGI) and CanniMed Therapeutics (TSE:CMED) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

CanniMed Therapeutics has lower revenue, but higher earnings than Organigram.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram	C$309.18M	0.74	-C$57.23M	C$0.60	2.65
CanniMed Therapeutics	N/A	N/A	N/A	N/A	N/A

In the previous week, Organigram's average media sentiment score of 0.00 equaled CanniMed Therapeutics'average media sentiment score.

Company	Overall Sentiment
Organigram	Neutral
CanniMed Therapeutics	Neutral

3.6% of Organigram shares are owned by institutional investors. 31.3% of Organigram shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Organigram has a net margin of 28.02% compared to CanniMed Therapeutics' net margin of 0.00%. Organigram's return on equity of 21.99% beat CanniMed Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram	28.02%	21.99%	-5.56%
CanniMed Therapeutics	N/A	N/A	N/A

Organigram presently has a consensus target price of C$3.13, indicating a potential upside of 96.54%. Given Organigram's stronger consensus rating and higher possible upside, analysts plainly believe Organigram is more favorable than CanniMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
CanniMed Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Organigram beats CanniMed Therapeutics on 8 of the 9 factors compared between the two stocks.

How does Organigram compare to Canopy Growth?

Organigram (TSE:OGI) and Canopy Growth (TSE:WEED) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

In the previous week, Canopy Growth's average media sentiment score of 0.76 beat Organigram's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Overall Sentiment
Organigram	Neutral
Canopy Growth	Positive

3.6% of Organigram shares are owned by institutional investors. Comparatively, 4.5% of Canopy Growth shares are owned by institutional investors. 31.3% of Organigram shares are owned by company insiders. Comparatively, 0.2% of Canopy Growth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Organigram has a net margin of 28.02% compared to Canopy Growth's net margin of -73.95%. Organigram's return on equity of 21.99% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram	28.02%	21.99%	-5.56%
Canopy Growth	-73.95%	-29.85%	-3.83%

Organigram has a beta of 1.779518, meaning that its share price is 78% more volatile than the broader market. Comparatively, Canopy Growth has a beta of 1.634762, meaning that its share price is 63% more volatile than the broader market.

Organigram has higher revenue and earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram	C$309.18M	0.74	-C$57.23M	C$0.60	2.65
Canopy Growth	C$293.63M	2.07	-C$1.05B	-C$0.67	N/A

Organigram currently has a consensus target price of C$3.13, suggesting a potential upside of 96.54%. Canopy Growth has a consensus target price of C$1.88, suggesting a potential upside of 38.89%. Given Organigram's stronger consensus rating and higher probable upside, analysts clearly believe Organigram is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Organigram beats Canopy Growth on 10 of the 14 factors compared between the two stocks.

How does Organigram compare to Fennec Pharmaceuticals?

Fennec Pharmaceuticals (TSE:FRX) and Organigram (TSE:OGI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Organigram has a consensus target price of C$3.13, suggesting a potential upside of 96.54%. Given Organigram's higher possible upside, analysts clearly believe Organigram is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Fennec Pharmaceuticals has a beta of 3.722406, meaning that its stock price is 272% more volatile than the broader market. Comparatively, Organigram has a beta of 1.779518, meaning that its stock price is 78% more volatile than the broader market.

Organigram has a net margin of 28.02% compared to Fennec Pharmaceuticals' net margin of -6.21%. Organigram's return on equity of 21.99% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fennec Pharmaceuticals	-6.21%	-13.34%	8.88%
Organigram	28.02%	21.99%	-5.56%

15.4% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 3.6% of Organigram shares are held by institutional investors. 16.2% of Fennec Pharmaceuticals shares are held by company insiders. Comparatively, 31.3% of Organigram shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Fennec Pharmaceuticals has higher earnings, but lower revenue than Organigram. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fennec Pharmaceuticals	C$59.22M	10.32	-C$800.44K	-C$0.12	N/A
Organigram	C$309.18M	0.74	-C$57.23M	C$0.60	2.65

In the previous week, Fennec Pharmaceuticals had 1 more articles in the media than Organigram. MarketBeat recorded 1 mentions for Fennec Pharmaceuticals and 0 mentions for Organigram. Fennec Pharmaceuticals' average media sentiment score of 0.90 beat Organigram's score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Fennec Pharmaceuticals	Positive
Organigram	Neutral

Summary

Fennec Pharmaceuticals beats Organigram on 9 of the 17 factors compared between the two stocks.

How does Organigram compare to Valens GroWorks?

Valens GroWorks (CVE:VGW) and Organigram (TSE:OGI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

Organigram has a consensus target price of C$3.13, indicating a potential upside of 96.54%. Given Organigram's stronger consensus rating and higher probable upside, analysts clearly believe Organigram is more favorable than Valens GroWorks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valens GroWorks	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Valens GroWorks' average media sentiment score of 0.00 equaled Organigram'saverage media sentiment score.

Company	Overall Sentiment
Valens GroWorks	Neutral
Organigram	Neutral

Valens GroWorks has higher earnings, but lower revenue than Organigram. Valens GroWorks is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valens GroWorks	C$27.50M	13.96	-C$22.41M	-C$0.18	N/A
Organigram	C$309.18M	0.74	-C$57.23M	C$0.60	2.65

Organigram has a net margin of 28.02% compared to Valens GroWorks' net margin of 0.00%. Organigram's return on equity of 21.99% beat Valens GroWorks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valens GroWorks	N/A	N/A	N/A
Organigram	28.02%	21.99%	-5.56%

3.6% of Organigram shares are owned by institutional investors. 31.3% of Organigram shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Organigram beats Valens GroWorks on 10 of the 13 factors compared between the two stocks.

Get Organigram News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OGI vs. The Competition

Export

Metric	Organigram	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$227.76M	C$12.25B	C$7.25B	C$12.64B
Dividend Yield	N/A	2.58%	2.53%	6.25%
P/E Ratio	2.65	792.20	274.10	39.38
Price / Sales	0.74	957.20	687.92	9.93
Price / Cash	3.85	90.26	77.08	82.29
Price / Book	0.44	12.47	12.85	4.73
Net Income	-C$57.23M	C$2.83B	C$3.49B	C$299.09M
7 Day Performance	-5.36%	4.03%	1.04%	-0.25%
1 Month Performance	16.91%	5.80%	5.39%	2.14%
1 Year Performance	-30.26%	10.00%	24.18%	27.60%

Organigram Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OGI Organigram	2.9356 of 5 stars	C$1.59 +0.6%	C$3.13 +96.5%	-30.3%	C$227.76M	C$309.18M	2.65	987
TLRY Tilray Brands	1.0862 of 5 stars	C$6.40 +2.7%	C$13.30 +107.8%	-62.0%	C$880.52M	C$915.45M	N/A	2,650
CMED CanniMed Therapeutics	N/A	N/A	N/A	N/A	C$668.44M	N/A	N/A	147,000
WEED Canopy Growth	2.0016 of 5 stars	C$1.35 flat	C$1.88 +38.9%	-33.2%	C$606.55M	C$293.63M	N/A	2,700
FRX Fennec Pharmaceuticals	0.1605 of 5 stars	C$17.00 flat	N/A	+40.5%	C$596.14M	C$59.22M	N/A	10	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:OGI) was last updated on 9/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Organigram (OGI) Competitors

OGI vs. TLRY, CMED, WEED, FRX, and VGW

How does Organigram compare to Tilray Brands?

Summary

How does Organigram compare to CanniMed Therapeutics?

Summary

How does Organigram compare to Canopy Growth?

Summary

How does Organigram compare to Fennec Pharmaceuticals?

Summary

How does Organigram compare to Valens GroWorks?

Summary

Media Sentiment Over Time

OGI vs. The Competition

Organigram Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Organigram (OGI) Competitors

OGI vs. TLRY, CMED, WEED, FRX, and VGW

How does Organigram compare to Tilray Brands?

Which has better earnings and valuation, OGI or TLRY?

Does the media prefer OGI or TLRY?

Is OGI or TLRY more profitable?

Do analysts prefer OGI or TLRY?

Do institutionals and insiders believe in OGI or TLRY?

Which has more volatility and risk, OGI or TLRY?

Summary

How does Organigram compare to CanniMed Therapeutics?

Which has preferable earnings & valuation, OGI or CMED?

Does the media prefer OGI or CMED?

Do insiders & institutionals believe in OGI or CMED?

Is OGI or CMED more profitable?

Do analysts prefer OGI or CMED?

Summary

How does Organigram compare to Canopy Growth?

Does the media prefer OGI or WEED?

Do insiders & institutionals hold more shares of OGI or WEED?

Is OGI or WEED more profitable?

Which has more volatility & risk, OGI or WEED?

Which has stronger earnings and valuation, OGI or WEED?

Do analysts prefer OGI or WEED?

Summary

How does Organigram compare to Fennec Pharmaceuticals?

Do analysts recommend FRX or OGI?

Which has more risk & volatility, FRX or OGI?

Is FRX or OGI more profitable?

Do institutionals and insiders have more ownership in FRX or OGI?

Which has stronger earnings and valuation, FRX or OGI?

Does the media favor FRX or OGI?

Summary

How does Organigram compare to Valens GroWorks?

Do analysts prefer VGW or OGI?

Does the media favor VGW or OGI?

Which has stronger earnings & valuation, VGW or OGI?

Is VGW or OGI more profitable?

Do insiders and institutionals believe in VGW or OGI?

Summary

Media Sentiment Over Time

OGI vs. The Competition

Organigram Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools